All In Biotech

Drug Trial Radar · NCT06007183

Long-term Follow-up Study to Evaluate Safety and Immunogenicity of CHIKV VLP Single or Booster Vaccination

A Long-term Follow-up Study to Evaluate Safety and Immunogenicity of a Chikungunya Virus Virus-like Particle Vaccine (CHIKV VLP) in Healthy Adults and Adolescents After Either a Single or Booster Vaccination Dosing Regimen

Last checked: Nov 20, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 715 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

715

Actual

Start

Aug 30, 2023

Primary completion

Feb 2028

Study completion Feb 2028

Sponsor

Lead sponsor
Bavarian NordicIndustry
Sponsor type
Industry
First posted
Aug 23, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this phase 3 multicenter, randomized, double-blind, placebo-controlled rollover study is to evaluate the safety and long-term immunogenicity of CHIKV VLP vaccine in adult and adolescent participants and to evaluate CHIKV VLP booster vaccine induced serum neutralizing antibody (SNA) response at 3 or 4 years post-initial CHIKV VLP vaccination.

Conditions

  • Chikungunya Virus Infection

Interventions

  • CHIKV VLP vaccine boosterBiological

    CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP) 40 µg, aluminum hydroxide 2% adjuvant, and formulation buffer supplied as a single dose of 0.8 mL in a pre-filled syringe, to be administered via intramuscular (IM) injection in the deltoid muscle.

  • Placebo boosterBiological

    Placebo is comprised of formulation buffer supplied as a single dose of 0.8 mL in a pre-filled syringe administered via IM injection in the deltoid muscle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants maintaining a preboost anti-CHIKV SNA titer ≥100 at yearly intervals up to 5 years post-initial vaccinationTime frame: 5 years post-initial vaccination in feeder study EBSI-CV-317-004 or EBSI-CV317-005 until booster
  2. Proportion of vaccine boosted participants with composite booster response at 21 days after booster vaccinationTime frame: 21 days after booster vaccination

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Alliance for Multispecialty Research, LLC

    Mobile, Alabama

  • Alliance for Multispecialty Research, LLC

    Tempe, Arizona

  • Optimal Research, LLC

    Melbourne, Florida

  • Suncoast Research Associates, LLC

    Miami, Florida

  • Synexus Clinical Research US, Inc.

    Chicago, Illinois

  • Optimal Research, LLC

    Peoria, Illinois

  • Alliance for Multispecialty Research, LLC

    Newton, Kansas

  • Alliance for Multispecialty Research, LLC

    Wichita, Kansas

  • Alliance for Multispecialty Research, LLC

    Lexington, Kentucky

  • Alliance for Multispecialty Research, LLC

    Kansas City, Missouri

  • Wr-Crcn, Llc

    Las Vegas, Nevada

  • Alliance for Multispecialty Research, LLC

    Las Vegas, Nevada

  • Rochester Clinical Research, LLC

    Rochester, New York

  • M3 Wake Research Inc.

    Raleigh, North Carolina

  • Velocity Clinical Research, Cleveland

    Cleveland, Ohio

  • Lynn Institute of Norman

    Norman, Oklahoma

  • Velocity Clinical Research, Medford

    Medford, Oregon

  • Velocity Clinical Research, Providence

    East Greenwich, Rhode Island

  • Velocity Clinical Research, Austin

    Cedar Park, Texas

  • DM Clinical Research

    Houston, Texas

  • BFHC Research, LLC

    San Antonio, Texas

  • DM Clinical Research

    Tomball, Texas

  • Velocity Clinical Research, Salt Lake City

    West Jordan, Utah

  • Alliance for Multispecialty Research, LLC

    Norfolk, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.